Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression

Published:November 18, 2009DOI:


      While most patients with depression respond to combinations of pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT), there are patients requiring other treatments. Deep brain stimulation (DBS) allows modulation of brain regions that are dysfunctional in depression. Since anhedonia is a feature of depression and there is evidence of dysfunction of the reward system, DBS to the nucleus accumbens (NAcc) might be promising.


      Ten patients suffering from very resistant forms of depression (treatment-resistant depression [TRD]), not responding to pharmacotherapy, psychotherapy, or ECT, were implanted with bilateral DBS electrodes in the NAcc. The mean (±SD) length of the current episode was 10.8 (±7.5) years; the number of past treatment courses was 20.8 (±8.4); and the mean Hamilton Depression Rating Scale (HDRS) was 32.5 (±5.3).


      Twelve months following initiation of DBS treatment, five patients reached 50% reduction of the HDRS (responders, HDRS = 15.4 [±2.8]). The number of hedonic activities increased significantly. Interestingly, ratings of anxiety (Hamilton Anxiety Scale) were reduced in the whole group but more pronounced in the responders. The [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography data revealed that NAcc-DBS decreased metabolism in the subgenual cingulate and in prefrontal regions including orbital prefrontal cortex. A volume of interest analysis comparing responders and nonresponders identified metabolic decreases in the amygdala.


      We demonstrate antidepressant and antianhedonic effects of DBS to NAcc in patients suffering from TRD. In contrast to other DBS depression studies, there was also an antianxiety effect. These effects are correlated with localized metabolic changes.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kessler R.C.
        • Berglund P.
        • Demler O.
        • Jin R.
        • Merikangas K.R.
        • Walters E.E.
        Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
        Arch Gen Psychiatry. 2005; 62: 593-602
        • Fava M.
        • Davidson K.G.
        Definition and epidemiology of treatment-resistant depression.
        Psychiatr Clin North Am. 1996; 19: 179-200
        • Rush A.J.
        • Trivedi M.H.
        • Wisniewski S.R.
        • Nierenberg A.A.
        • Stewart J.W.
        • Warden D.
        • et al.
        Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report.
        Am J Psychiatry. 2006; 163: 1905-1917
        • Holtzheimer P.E.
        • Nemeroff C.B.
        Novel targets for antidepressant therapies.
        Curr Psychiatry Rep. 2008; 10: 465-473
        • Schlaepfer T.
        • Lieb K.
        Deep brain stimulation for treatment refractory depression.
        Lancet. 2005; 366: 1420-1422
        • Krishnan V.
        • Nestler E.J.
        The molecular neurobiology of depression.
        Nature. 2008; 455: 894-902
        • Berton O.
        • Nestler E.J.
        New approaches to antidepressant drug discovery: Beyond monoamines.
        Nat Rev Neurosci. 2006; 7: 137-151
        • Lozano A.M.
        • Mayberg H.S.
        • Giacobbe P.
        • Hamani C.
        • Craddock R.C.
        • Kennedy S.H.
        Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression.
        Biol Psychiatry. 2008; 64: 461-467
        • Malone Jr, D.A.
        • Dougherty D.D.
        • Rezai A.R.
        • Carpenter L.L.
        • Friehs G.M.
        • Eskandar E.N.
        • et al.
        Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression.
        Biol Psychiatry. 2009; 65: 267-275
        • Schlaepfer T.E.
        • Cohen M.X.
        • Frick C.
        • Kosel M.
        • Brodesser D.
        • Axmacher N.
        • et al.
        Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression.
        Neuropschopharmacology. 2008; 33: 368-377
        • Gorwood P.
        Neurobiological mechanisms of anhedonia.
        Dialogues Clin Neurosci. 2008; 10: 291-299
        • Epstein J.
        • Pan H.
        • Kocsis J.H.
        • Yang Y.
        • Butler T.
        • Chusid J.
        • et al.
        Lack of ventral striatal response to positive stimuli in depressed versus normal subjects.
        Am J Psychiatry. 2006; 163: 1784-1790
        • Tremblay L.K.
        • Naranjo C.A.
        • Graham S.J.
        • Herrmann N.
        • Mayberg H.S.
        • Hevenor S.
        • et al.
        Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe.
        Arch Gen Psychiatry. 2005; 62: 1228-1236
        • Synofzyk M.
        • Schlaepfer T.E.
        Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes.
        J Biotechnol. 2008; 3: 1511-1520
        • Hamilton M.
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1967; 6: 278-296
        • Rosenthal S.H.
        • Klerman G.L.
        Endogenous features of depression in women.
        Can Psychiatr Assoc J. 1966; 11: 11-16
        • Endicott J.
        • Cohen J.
        • Nee J.
        • Fleiss J.
        • Sarantakos S.
        Hamilton Depression Rating Scale.
        Arch Gen Psychiatry. 1981; 38: 98-103
        • Montgomery S.A.
        • Åsberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Hamilton M.
        HAMA Hamilton Anxiety Scale.
        in: Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD1976: 193-198
        • Beck A.
        Beck Depression Inventory: Manual.
        Psychological Corporation, San Antonio, TX1987
        • Rush A.J.
        • Gullion C.M.
        • Basco M.R.
        • Jarrett R.B.
        • Trivedi M.H.
        The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
        Psychol Med. 1996; 26: 477-486
        • Franke G.
        SCL-90-R. Die Symptom-CHeckliste von Derogatis (Deutsche Version).
        Beltz-Verlag, Weinheim, Germany1995
        • Hautzinger M.
        Kognitive Verhaltenstherapie bei Depressionen.
        Beltz, München, Weinheim, Germany2000
        • Lewinsohn P.M.
        • Graf M.
        Pleasant activities and depression.
        J Consult Clin Psychol. 1973; 41: 261-268
        • Deuschl G.
        • Schade-Brittinger C.
        • Krack P.
        • Volkmann J.
        • Schafer H.
        • Botzel K.
        • et al.
        A randomized trial of deep-brain stimulation for Parkinson's disease.
        N Engl J Med. 2006; 355: 896-908
        • Mayberg H.
        Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment.
        Br Med Bull. 2003; 65: 193-207
        • Mayberg H.S.
        • Liotti M.
        • Brannan S.K.
        • McGinnis S.
        • Mahurin R.K.
        • Jerabek P.A.
        • et al.
        Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness.
        Am J Psychiatry. 1999; 156: 675-682
        • Ressler K.J.
        • Mayberg H.S.
        Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic.
        Nat Neurosci. 2007; 10: 1116-1124
        • Mayberg H.
        • Lozano A.
        • Voon V.
        • McNeely H.
        • Seminowicz D.
        • Hamani C.
        • et al.
        Deep brain stimulation for treatment-resistant depression.
        Neuron. 2005; 45: 651-660
        • Krishnan V.
        • Han M.H.
        • Graham D.L.
        • Berton O.
        • Renthal W.
        • Russo S.J.
        • et al.
        Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions.
        Cell. 2007; 131: 391-404
        • Berton O.
        • McClung C.A.
        • DiLeone R.J.
        • Krishnan V.
        • Renthal W.
        • Russo S.J.
        • et al.
        Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress.
        Science. 2006; 311: 864-868
        • Cohen M.X.
        • Axmacher N.
        • Lenartz D.
        • Elger C.E.
        • Sturm V.
        • Schlaepfer T.E.
        Neuroelectric signatures of reward learning and decision-making in the human nucleus accumbens.
        Neuropsychopharmacology. 2009; 34: 1649-1658
        • Gutman D.A.
        • Holtzheimer P.E.
        • Behrens T.E.
        • Johansen-Berg H.
        • Mayberg H.S.
        A tractography analysis of two deep brain stimulation white matter targets for depression.
        Biol Psychiatry. 2009; 65: 276-282
        • Cohen M.X.
        • Axmacher N.
        • Lenartz D.
        • Elger C.E.
        • Sturm V.
        • Schlaepfer T.E.
        Good vibrations: Cross-frequency coupling in the human nucleus accumbens during reward processing.
        J Cogn Neurosci. 2009; 21: 875-879
        • Nitschke J.B.
        • Sarinopoulos I.
        • Oathes D.J.
        • Johnstone T.
        • Whalen P.J.
        • Davidson R.J.
        • Kalin N.H.
        Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response.
        Am J Psychiatry. 2009; 166: 302-310
        • Schatzberg A.F.
        • Kraemer H.C.
        Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression.
        Biol Psychiatry. 2000; 47: 736-744
        • Rush A.J.
        • Sackeim H.A.
        • Marangell L.B.
        • George M.S.
        • Brannan S.K.
        • Davis S.M.
        • et al.
        Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: A naturalistic study.
        Biol Psychiatry. 2005; 58: 355-363
        • Sackeim H.A.
        The definition and meaning of treatment-resistant depression.
        J Clin Psychiatry. 2001; 62: 10-17

      Linked Article

      • Nucleus Accumbens Deep Brain Stimulation Did Not Prevent Suicide Attempt in Tourette Syndrome
        Biological PsychiatryVol. 68Issue 4
        • Preview
          Deep brain stimulation (DBS) in the nucleus accumbens has been reported to decrease ratings of depression and anxiety in treatment-resistant depression (1). Does DBS in the nucleus accumbens also hold a preventive potential against the development of a major depressive episode when applied in Tourette syndrome?
        • Full-Text
        • PDF
      • Hypomania Following Bilateral Ventral Capsule Stimulation in a Patient with Refractory Obsessive-Compulsive Disorder
        Biological PsychiatryVol. 68Issue 2
        • Preview
          Bewernick et al. (1) demonstrated the antidepressant and antianxiety effects of deep brain stimulation (DBS) to the nucleus accumbens (NAc) in patients suffering from treatment-resistant depression. Deep brain stimulation has also been proposed in the management of treatment-refractory obsessive-compulsive disorder (OCD), and several clinical trials have shown positive results. The US Food and Drug Administration granted DBS a humanitarian device exemption for OCD in 2009 (2). We report an ethnic Chinese male with OCD who developed hypomania after bilateral DBS in the ventral capsules, close to the NAc, and review hypomanic or manic cases in OCD trials.
        • Full-Text
        • PDF